Résumé
L’œsophage de Barrett se définit comme le remplacement de l’épithélium pavimenteux pluristratifié du bas œsophage par une muqueuse cylindrique métaplasique. C’est sur la muqueuse de type spécialisé que se développent les foyers de dysplasie et de cancérisation: raison pour laquelle il est impératif de les mettre en évidence et de bien les localiser pour assurer un suivi correct du patient par une standardisation des prélèvements. La réalisation d’une cartographie des prélèvements associée à la pratique de colorationin vivo améliore le rendement diagnostique et facilite le suivi des patients. Des examens immunohistochimiques réalisés sur les biopsies de certains cas peuvent aider à sélectionner des patients à risque.
Summary
Barrett’s œsophagus is defined as the replacement of the pluristratified squamous epithelium of the lower esophagus by a metaplastic columnar mucosa. It is the site where areas of dysplasiacarcinoma develop. It is imperative to identify and localise these through the standardisation of sampling to ensure proper patient followup. Systematic mapping and in vivostaining improves diagnostic yield and facilitates patient followup. Immunohistochemical examination can help to select patients at risk.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Références
PAULL A., TRIER J.S., DALTON M.D. — The histologic spectrum of Barrett’s esophagus.N. Engl. J. Med., 1976,295, 476–480.
SPECHLER S.J., GOYAL R.K. — Barrett’s esophagus.N. Engl. I. Med., 1986, 315–362.
MAINGUET P., JOURET A. — Surveillance de l’endobrachycesophage.Acta Endoscopica, 1992,22, 511–517.
JOURET A., MAINGUET P., AKELE M.Th. — Systematic mapping and histo-endoscopy study of columnar lined epithelium in extended Barrett’s esophagus.Acta Gastroent. Belg., 1993,56, 1 C16.
GEBOES K., Van EYCKEN P. — The diagnosis of dysplasia and malignancy in Barrett’s esophagus.Histopathology, 2000,37, 99–107.
CADIOT G. — Endoscopic et surveillance de la muqueuse de Barrett.Castroenterol. Clin. Biol., 2003,27, 689–691.
SPECHLER S.J. — Barrett’s esophagus.N. Engl. J. Med., 2002,346, 836–842.
RIDDELL R.H., GOLDMAN H., RANSOHOFF D.F., APPELMAN H.D., FENOGLIO C.M., HAGGITT R.C. — Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications.Hum. Pathol., 1983,414, 931–968.
SAMPLINER R.E. and the Practice Parameters Committee of the American College of Gastroenterology. — Practice guidelines on the diagnosis, surveillance and therapy of Barrett’s esophagus.Am. J. Gastroent., 1998,93, 1028–1032 and Update guidelinesAm. J. Gastroent., 2002,97, 1888–1895.
BUTTAR N.S., WANG K.K., SEBO T.J., RIEHLE D.M., KRISNADATH K.K., LUTZKE L.S. — Extent of high grade dysplasia in Barrett’s esophagus correlates with risk of adenocarcinoma.Gastroenterology, 2001,120, 1630–1639.
BIAN Y.S., OWTERHELD M.C., BOSMAN F.T., BENHATTAR J., FONTOLLIET C. — P53 gene mutation and protein accumulation during neoplastic progression in Barrett’s esophagus.Mod. Pathol, 2001,14, 397–403.
GIMÉNEZ A., DE HARO L.M., PARRILLA P., BERMEJO J., PEREZ-GUILLERMO M., ORTIZ M.A. — Immunohistochemical detection of P53 protein could improve the management of some patients with Barrett esophagus and mild histologic alterations.Arch. Pathol. Lab. Med., 1999,123, 1260–1263.
WESTON A.P., BANERJEE S.K., SHARMA P., TRAN T.M, RICHARDS R., CHERIAN R. — P53 protein overexpression in low grade dysplasia (LGD) in Barrett’s esophagus: immunohistochemical marker predictive of progression.Am. J. Gastroent., 2001,96, 1321–1323.
ROUX-LECLERCQ N., TURLIN B., SUTHERLAND F., HERESBACH N., LAUNOIS B., CAMPION J.P., RAMEE M.P. — Analysis of KI67, p53, and Bcl2 expression in the dysplasia-carcinoma sequence of Barrett’s esophagus.Oncol. Rep., 1999,6, 877–882.
FLEJOU J.P., POTET F., MUZEAU F. — Overexpression of p 53 protein in Barrett’s syndrome with malignant transformation.J. Clin. Pathol, 1993,46, 330–333.
GLEESON C.M., SLOAN J.M., MCMANUS D.T. — Comparison of P53 and DNA content abnormalities in adenocarcinoma of the esophagus and gastric cardia.Br. J. Cancer, 1998,77, 277–286.
HALL P.A., WOODMAN A.C., CAMPBELL S.J., SHEPERD N.A. — Expression of the p53 homologue p63alpha and DeltaNp63alpha in the neoplastic sequence of Barrett’s oesophagus: correlation with morphology and p53.Gut, 2001,49, 618–623.
REID B.J., HAGGITT R.C., RUBIN C.E., ROTH G., SURAWICZ C.M., Van BELLE G.et al.— Observer variation in the diagnosis of dysplasia in Barrett’s esophagus.Hum. Pathol., 1988,19, 166–178.
SAGAN C., FLEJOU J.F., DIEBOLD M.D., POTET F., LE BODIC M.F. — Reproductiblé des critères histologiques de dysplasie sur muqueuse de Barrett.Gastroenterol. Clin. Biol., 1994,18, D31-D34.
ORMSBY A.H., VAEZI M.F., RICHTER J.E., GOLDBLUM J.R. — Cytokeratin immunoreactivity patterns in the diagnosis of short-segment Barrett’s oesophagus.Gastroenterology, 2000,119, 683–69.
COUVELARD A., CAUVIN J.M., GOLDAIN D., ROTEN-BERG A., ROBASZKIEWICZ M., FLEJOU J.F. — Cytokeratine immunoreactivity of intestinal metaplasia at normal oesophagogastric junction indicates its aetiology.Gut, 2001,49, 761–766.
DEBONGNIES J.C., MACCHI H., MAINGUET P. — Schéma planimétrique destiné à la surveillance de l’œsophage à haut risque.Acta Endoscopica, 1981,11, 353–356.
ROBEY S.S., HAMILTON S.R., GUPTA P.K., EROZAN Y.S. — Diagnostic value of cytopathology in Barrett esophagus and associated carcinoma.Am. J. Clin. Pathol., 1988,89, 493–498.
GEISINGER K.R., TEOT L.A., RICHTER J.E. — A comparative cytopathologic and histologie study of atypia, dysplasia, and adenocarcinoma in Barrett’s esophagus.Cancer, 1992, 69–78.
FENNERTY M.B. — La chromoscopie dans le diagnostic et la surveillance de l’œsophage de Barrett.Acta Endoscopica, 2001,52, 151–159.
CANTO M.I., SETRAKIAN S., PETRAS R.E., BLADES E., CHAK A., SIVAK M.V. — Méthylène blue selectively stains intestinal metaplasia in Barrett’s esophagus.Gastrointest. Endosc., 1996,44, 1–7.
CANTO M.I.F., SETRAKAIN S., WILLIS J.E. — Méthylène blue staining of dysplastic and non dysplastic Barrett’s esophagus: anin vivo andex vivo study.Endoscopy, 2001,33, 391–400.
CANTO M.I.F., SETRAKIAN S., WILLIS J., CHAK A., PETRAS R., POWE N., SIVAK M.V. — Méthylène blue — directed biopsies improve detection of intestinal metaplasia and dysplasia in Barrett’s esophagus.Gastrointest. Endosc., 2000,57, 5–10.
GIOVANNINI M. — De la dysplasie à la dysphagie.Gastroenterol. Clin. Biol., 2003,27, B143-B145.
WO J.M., RAY M.B., MAYFIELD-STOKES S., AL-SABBAGH G., GEBRAIL F., SLO S. — Comparison of méthylène blue-directed biopsies and conventional biopsies in the detection of intestinal mataplasia and dysplasia in Barrett’s esophagus: a preliminary study.Gastrointest. Endosc., 2001,54, 409–413.
GUELRUD M., HERRERA I. ESSENFELD H.et al. — Enhanced magnification endoscopy: a new technique to identify specialized metaplasia in Barrett’s esophagus.Gastrointest. Endosc., 2001,55, 559–565.
EGGER K., WERNER M., MEINING A., OTT R., ALLES-CHER H.D., HOFLER H. — Biopsy surveillance is still necessary in patients with Barrett’s esophagus despite new endoscopic imaging techniques.Gut, 2003,52, 18–23.
Author information
Authors and Affiliations
About this article
Cite this article
Jouret, A., Delmotte, J.S. Méthodologie des biopsies dans l’œsophage de Barrett. Acta Endosc 33, 727–731 (2003). https://doi.org/10.1007/BF03002611
Issue Date:
DOI: https://doi.org/10.1007/BF03002611